Young Blood Plasma Beneficial in Parkinson Disease


Six-month results show significant improvements in motor symptoms, mentation, behavior, and mood, with a prolonged residual benefit.

Dr Dian Ginsberg, MD

Dian Ginsberg, MD,staff OB GYN, Memorial Hermann Hospital and Park Plaza Hospital

Dian Ginsberg, MD

The Neurology Center has announced that the use of 25 ml/kg intravenous NuPlasma young Fresh Frozen Plasma (yFFP) administered in 2 doses over 3 days has been associated with a number of motor symptom reductions during in-person neurologist assessments at 6 months for subjects with Parkinson disease.

The 6-month data showed that yFFP was linked to a number of motor symptom reductions including action tremor (-80.6%), tremor at rest (-50.8%), and a number of instances of bradykinesia, including postural stability (-62.5%) and body bradykinesia (-25%). Additionally, subjects treated with yFFP saw reductions in depression (-77.5%), motivation and initiative (-43.8%), and intellectual impairment (-38.9%), as well as improvements in sensory complaints (-67.86%), handwriting (-34.9%), and swallowing (-32.5%).

“It has been a privilege to observe and present the results of this yFFP investigation,” Dian Ginsberg, MD, staff OB/GYN, Memorial Hermann Hospital and Park Plaza Hospital, one of the 3 physicians leading the study said in a statement.1 “Parkinson disease is one of a larger group of neurological conditions called motor system disorders and prior to making public these results from young blood plasma infusions, no available medications reversed the progression of the disease. Young blood plasma infusions have now conclusively shown a lasting and unprecedented success in broadly improving patient outcomes. It is with great encouragement that we believe the combination of microbiome correction, inflammation reduction and infusions of yFFP can mediate neurodegeneration in a significant and meaningful way.”

The randomized, double-blind, placebo-controlled trial is designed to evaluate the efficacy of 25 ml/kg intravenous NuPlasma yFFP administered in 2 doses throughout a 3-day period in 20 subjects.

In April, the Neurology Center announced 3-month data which also demonstrated that yFFP was associated with statistically significant improvements in a number of neurological assessments for patients with Parkinson disease. The randomized and double-blind investigation showed yFFP was linked to overall improvements in complications of therapy (50%), motor examinations (19.2%), mentation, behavior, and mood (12.9%), and activities of daily living (7.9%).

Previous 1-month data revealed that subjects receiving yFFP achieved improvements in 30 out of 43 assessment categories, with yFFP outperforming the placebo in every assessment subset.2


Young Blood Plasma Parkinson's Disease Investigation Six-Month Results Show Dramatic Improvements In Motor Symptoms and Mentation, Behavior and Mood [news release]. Houston, Texas: The Neurology Center; Aug. 7, 2019. Accessed Aug. 7, 2019.

Related Videos
Bruce Cree, MD
Christos Papadelis, PhD
Ro'ee Gilron, PhD
Monica Verduzco-Gutierrez, MD
Shahid Nimjee, MD, PhD
Peter J. McAllister, MD, FAAN
Video 6 - "Utilization of Neuroimaging in Alzheimer’s Disease"
Video 5 - "Contribution of Multiple Pathways to the Development of Alzheimer’s Disease"
Michael Levy, MD, PhD
© 2024 MJH Life Sciences

All rights reserved.